Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 457
- Registration Number
- NCT03099382
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 157
- Registration Number
- NCT03092895
- Locations
- 🇨🇳
Cancer Hospital of Henan province, Zhengzhou, Henan, China
🇨🇳Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03085069
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute (GLCI),Guangdong General Hospital (GGH), Guangzhou, Guangdong, China
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT03083041
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
- Conditions
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03080805
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT03075462
- Locations
- 🇨🇳
Beijing Cancer Hosptial, Beijing, Beijing, China
Food-Effect and Metabolism Study in Healthy Subjects
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03062982
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03026881
- Locations
- 🇨🇳
The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03006159
A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT03003884
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, Beijing, China